| Literature DB >> 34949653 |
Fresia Pareja1, Ryan N Ptashkin1, David N Brown1, Fatemeh Derakhshan1, Pier Selenica1, Edaise M da Silva1, Andrea M Gazzo1, Arnaud Da Cruz Paula2, Kelsey Breen3, Ronglai Shen4, Antonio Marra1, Ahmet Zehir1, Ryma Benayed1, Michael F Berger1, Ozge Ceyhan-Birsoy1, Sowmya Jairam1, Margaret Sheehan3, Utsav Patel1, Yelena Kemel5, Jacklyn Casanova-Murphy1, Christopher J Schwartz1, Mahsa Vahdatinia1, Elizabeth Comen6, Laetitia Borsu1, Xin Pei7, Nadeem Riaz7, David H Abramson8, Britta Weigelt1, Michael F Walsh3,8, Anna-Katerina Hadjantonakis9, Marc Ladanyi1, Kenneth Offit3,5, Zsofia K Stadler3,5, Mark E Robson3,5,6, Jorge S Reis-Filho1, Diana Mandelker1.
Abstract
Mosaic mutations in normal tissues can occur early in embryogenesis and be associated with hereditary cancer syndromes when affecting cancer susceptibility genes (CSG). Their contribution to apparently sporadic cancers is currently unknown. Analysis of paired tumor/blood sequencing data of 35,310 patients with cancer revealed 36 pathogenic mosaic variants affecting CSGs, most of which were not detected by prior clinical genetic testing. These CSG mosaic variants were consistently detected at varying variant allelic fractions in microdissected normal tissues (n = 48) from distinct embryonic lineages in all individuals tested, indicating their early embryonic origin, likely prior to gastrulation, and likely asymmetrical propagation. Tumor-specific biallelic inactivation of the CSG affected by a mosaic variant was observed in 91.7% (33/36) of cases, and tumors displayed the hallmark pathologic and/or genomic features of inactivation of the respective CSGs, establishing a causal link between CSG mosaic variants arising in early embryogenesis and the development of apparently sporadic cancers. SIGNIFICANCE: Here, we demonstrate that mosaic variants in CSGs arising in early embryogenesis contribute to the oncogenesis of seemingly sporadic cancers. These variants can be systematically detected through the analysis of tumor/normal sequencing data, and their detection may affect therapeutic decisions as well as prophylactic measures for patients and their offspring. See related commentary by Liggett and Sankaran, p. 889. This article is highlighted in the In This Issue feature, p. 873. ©2021 American Association for Cancer Research.Entities:
Mesh:
Year: 2022 PMID: 34949653 PMCID: PMC8983494 DOI: 10.1158/2159-8290.CD-21-1110
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272